Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity
| Autor: | Federica Vigna-Taglianti, Michela Stoppo, Lorenzo Leggio, Mauro Bernardi, Giorgio Zoli, Arfedele Del Re, Fabio Caputo, Sara Francini, R Brambilla, Giovanni Addolorato |
|---|---|
| Přispěvatelé: | Caputo F, Francini S, Brambilla R, Vigna Taglianti F, Stoppo M, Del Re A, Leggio L, Addolorato G, Zoli G, Bernardi M. |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Sodium Oxybate GABA Agents Temperance Alcohol-dependence Alcohol Craving Alcohol pharmacotherapy Comorbidity Craving for and abuse of sodium oxybate Psychiatric co-morbidity Sodium oxybate Group B Biomarkers Pharmacological NO chemistry.chemical_compound Alcohol and health Recurrence Internal medicine Medicine Humans Pharmacology (medical) Alcoholics Psychiatry Biological Psychiatry Pharmacology Neurology Neurology (clinical) Psychiatry and Mental Health Ethanol business.industry Mental Disorders Settore MED/09 - MEDICINA INTERNA Alcohol dependence medicine.disease Substance Withdrawal Syndrome Psychiatry and Mental health Alcoholism Treatment Outcome psychiatric comorbidity chemistry Female medicine.symptom business Alcohol Abstinence Alcohol Deterrents |
| Zdroj: | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 21(6) |
| ISSN: | 1873-7862 |
| Popis: | Sodium oxybate (SMO) is a GABA-ergic drug currently used for the treatment of alcohol-dependence in some European countries. In particular, clinical studies have shown a role of SMO in promoting alcohol abstinence, as well as in relieving withdrawal symptoms. The aim of this study was to describe alcohol abstinence and the onset of craving for and abuse of SMO in alcohol-dependent subjects with and without psychiatric co-morbidity. Forty-eight patients were enrolled and classified into two groups: group A (20 alcoholics without any psychiatric co-morbidity) and group B (28 alcoholics with a psychiatric co-morbidity). All patients were treated with oral SMO (50 mg/kg of body weight t.i.d.) for 12 weeks. Alcohol abstinence as well as alcohol drinking during the 12 weeks of treatment did not differ between the two groups at the end of treatment (p=0.9). In addition, a reduction of alcohol intake in both groups has been observed (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect